Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Weight change in adults tied to colorectal adenoma risk
Weight loss during adulthood, particularly among overweight or obese individuals, is associated with a reduction in the risk of developing distal colorectal adenomas – a precursor to colorectal cancer, whereas weight gain increased its risk, according to findings from the PLCO* Cancer Screening Trial.
Weight change in adults tied to colorectal adenoma risk
04 Mar 2022Universal HCV screening in pregnancy: A step toward reducing transmission?
Universal screening for hepatitis C virus (HCV) in pregnant individuals resulted in improved detection and a potential reduction in perinatal transmission, according to a study presented at CROI 2022.
Universal HCV screening in pregnancy: A step toward reducing transmission?
01 Mar 2022Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
In patients with gout and concurrent chronic kidney disease (CKD), the risk of mortality does not seem to increase with initiation of allopurinol, achieving target serum urate (SU) level with allopurinol, or treatment dose escalation, a study has shown.
Allopurinol use, dose escalation do not increase mortality in gout patients with CKD
01 Mar 2022KEYNOTE-394 a win for Asians with advanced HCC
Combining pembrolizumab with best supportive care (BSC) improved survival and response when used as second-line therapy in Asians with advanced hepatocellular carcinoma (HCC).
KEYNOTE-394 a win for Asians with advanced HCC
01 Mar 2022STRIDE regimen boosts OS in unresectable HCC
The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.
STRIDE regimen boosts OS in unresectable HCC
25 Feb 2022Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?
In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.